Radiographic Progression of Patients With Psoriatic Arthritis Who Achieve Minimal Disease Activity in Response to Golimumab Therapy: Results Through 5 Years of a Randomized, Placebo‐Controlled Study

Radiographic Progression of Patients With Psoriatic Arthritis Who Achieve Minimal Disease Activity in Response to Golimumab Therapy: Results Through 5 Years of a Randomized, Placebo‐Controlled Study

Bibliographic Details
Main Authors:	Kavanaugh, Arthur, van der Heijde, Désirée, Beutler, Anna, Gladman, Dafna, Mease, Philip, Krueger, Gerald G., McInnes, Iain B., Helliwell, Philip, Coates, Laura C., Xu, Stephen
Format:	Online
Language:	English
Published:	John Wiley and Sons Inc. 2016
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5066795/

Similar Items

Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study)
by: Kavanaugh, Arthur, et al.
Published: (2014)

Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study
by: Kavanaugh, Arthur, et al.
Published: (2013)

Patient-Reported Outcomes and the Association With Clinical Response in Patients With Active Psoriatic Arthritis Treated With Golimumab: Findings Through 2 Years of a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
by: Kavanaugh, Arthur, et al.
Published: (2013)

Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab
by: Wagner, Carrie L, et al.
Published: (2013)

Erratum to: Secukinumab: A New Treatment Option for Psoriatic Arthritis
by: Mease, Philip, et al.
Published: (2016)

Classification and Outcome Measures for Psoriatic Arthritis
by: Ying Ying Leung, et al.
Published: (2018-09-01)

Qualifying Unmet Needs and Improving Standards of Care in Psoriatic Arthritis
by: Helliwell, Philip, et al.
Published: (2014)

The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial
by: Braun, Jürgen, et al.
Published: (2014)

Brief Report: Secukinumab Provides Significant and Sustained Inhibition of Joint Structural Damage in a Phase III Study of Active Psoriatic Arthritis
by: van der Heijde, Désirée, et al.
Published: (2016)

Improvements in productivity at paid work and within the household, and increased participation in daily activities after 24 weeks of certolizumab pegol treatment of patients with psoriatic arthritis: results of a phase 3 double-blind randomised placebo-controlled study
by: Kavanaugh, A, et al.
Published: (2015)

Infliximab (Remicade) in the treatment of psoriatic arthritis
by: Mease, Philip
Published: (2006)

The association between sonographic enthesitis and radiographic damage in psoriatic arthritis
by: Ari Polachek, et al.
Published: (2017-08-01)

Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor
by: Kavanaugh, Arthur, et al.
Published: (2014)

Recent advances in understanding and managing psoriatic arthritis
by: Gladman, Dafna D.
Published: (2016)

Synovial Tissue Response to Treatment in Psoriatic Arthritis
by: Codullo, Veronica, et al.
Published: (2011)

Maintenance of Clinical Efficacy and Radiographic Benefit Through Two Years of Ustekinumab Therapy in Patients With Active Psoriatic Arthritis: Results From a Randomized, Placebo‐Controlled Phase III Trial
by: Kavanaugh, Arthur, et al.
Published: (2015)

Systematic literature review of domains assessed in psoriatic arthritis to inform the update of the psoriatic arthritis core domain set
by: Kalyoncu, Umut, et al.
Published: (2016)

The GOLMePsA study protocol: an investigator-initiated, double-blind, parallel-group, randomised, controlled trial of GOLimumab and methotrexate versus methotrexate in early diagnosed psoriatic arthritis using clinical and whole body MRI outcomes
by: Gabriele De Marco, et al.
Published: (2017-07-01)

Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials
by: Kavanaugh, Arthur, et al.
Published: (2014)

Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study
by: Braun, Jürgen, et al.
Published: (2011)

Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1)
by: Sieper, Joachim, et al.
Published: (2013)

Managing Patients with Psoriatic Disease: The Diagnosis and Pharmacologic Treatment of Psoriatic Arthritis in Patients with Psoriasis
by: Mease, Philip J., et al.
Published: (2014)

Erratum to: Apremilast: A Phosphodiesterase 4 Inhibitor for the Treatment of Psoriatic Arthritis
by: Mease, Philip J.
Published: (2015)

Apremilast: A Phosphodiesterase 4 Inhibitor for the Treatment of Psoriatic Arthritis
by: Mease, Philip J.
Published: (2014)

Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis
by: Kay, Jonathan, et al.
Published: (2015)

Golimumab in radiographic and nonradiographic axial spondyloarthritis: a review of clinical trials
by: Toussirot, Eric, et al.
Published: (2016)

Ustekinumab in the Treatment of Psoriasis and Psoriatic Arthritis
by: Savage, Laura J., et al.
Published: (2015)

Structural damage in rheumatoid arthritis as visualized through radiographs
by: van der Heijde, Désirée
Published: (2002)

Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol
by: van der Heijde, D, et al.
Published: (2014)

Achieving minimal disease activity in psoriatic arthritis predicts meaningful improvements in patients’ health-related quality of life and productivity
by: Laura C. Coates, et al.
Published: (2018-08-01)

Serum markers associated with clinical improvement in patients with ankylosing spondylitis treated with golimumab
by: Wagner, Carrie, et al.
Published: (2011)

Serum biomarkers and changes in clinical/MRI evidence of golimumab-treated patients with ankylosing spondylitis: results of the randomized, placebo-controlled GO-RAISE study
by: Inman, Robert D., et al.
Published: (2016)

A Randomized, Double‐Blind, Placebo‐Controlled, Sixteen‐Week Study of Subcutaneous Golimumab in Patients With Active Nonradiographic Axial Spondyloarthritis
by: Sieper, J., et al.
Published: (2015)

Macrophage dysfunction in Psoriatic Arthritis
by: Wenink, Mark H, et al.
Published: (2011)

Phosphodiesterase 4 Inhibition in the Treatment of Psoriasis, Psoriatic Arthritis and Other Chronic Inflammatory Diseases
by: Wittmann, Miriam, et al.
Published: (2013)

Golimumab for the treatment of ulcerative colitis
by: Löwenberg, Mark, et al.
Published: (2014)

Golimumab in unresponsive ulcerative colitis
by: Lippert, Elisabeth, et al.
Published: (2014)

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study
by: Braun, Jürgen, et al.
Published: (2011)

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study
by: Deodhar, Atul, et al.
Published: (2015)

Psoriatic arthritis: Pathogenesis and novel immunomodulatory approaches to treatment
by: Cassell, Sarah, et al.
Published: (2005)